ABSTRACT
Malignant mesenchymal tumors of the uterus are relatively uncommon. Their annual worldwide incidence is between 0.5 and 3 cases per 100 women, accounting for 3% to 5% of all uterine malignancies (1).
These tumors can be classified as pure (only malignant mesenchymal component) and mixed mesodermal tumors (MMT) (malignant mesenchymal component associated with a benign or malignant epithelial component) (Table 1). The most frequent categories of mesenchymal tumors are leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) in the pure type, and carcinosarcoma in themixed type.
